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Abstract: Bacterial resistance to present antibiotics is emerging at a high pace that makes the
development of new treatments a must. At the same time, the development of novel antibiotics
for resistant bacteria is a slow-paced process. Amid the massive need for new drug treatments to
combat resistance, time and effort preserving approaches, like the prodrug approach, are most needed.
Prodrugs are pharmacologically inactive entities of active drugs that undergo biotransformation before
eliciting their pharmacological effects. A prodrug strategy can be used to revive drugs discarded due
to a lack of appropriate pharmacokinetic and drug-like properties, or high host toxicity. A special
advantage of the use of the prodrug approach in the era of bacterial resistance is targeting resistant
bacteria by developing prodrugs that require bacterium-specific enzymes to release the active drug.
In this article, we review the up-to-date implementation of prodrugs to develop medications that are
active against drug-resistant bacteria.
Keywords: prodrugs; biotransformation; targeting; β-lactam antibiotics; β-lactamases; pathogens;
resistance
1. Introduction
Nowadays, the issue of pathogens resistant to drugs and the urgent need for new compounds
that are capable of eradicating these pathogens are well known and understood. Most of the resistance
mechanisms by bacteria have been discovered and described, such as enzymatic degradation, target
modification, overexpression of efflux pumps and decreased uptake. Multidrug-resistant bacteria
show resistance to three or more antibiotic classes, and are a major cause of mortality as indicated by
the World Health Organization (WHO) [1].
Penicillin was discovered in the 1940s, and shortly after, resistance was developed. By the 1950s,
many β-lactam antibiotics were discovered; however, resistance was identified in the 1960s. Later on,
fluoroquinolones were introduced to treat Gram-negative bacteria in the 1980s, but resistance was
quickly developed due to chromosomal mutations. Antibiotic discovery continued over decades, and
millions of drugs were introduced to the market; this has led to less expensive antibiotics and the
irresponsible dispensing of antibiotics without prescriptions, with the absence of regulatory guidelines
in many countries. This has all contributed to the development of resistant strains (Table 1) [2,3].
Molecules 2020, 25, 1543; doi:10.3390/molecules25071543 www.mdpi.com/journal/molecules
Molecules 2020, 25, 1543 2 of 16
Table 1. A timeline of antibiotic introduction and the development of antibiotic resistance.
Antibiotics Date Introduced Date of Resistance Development
Penicillin Discovery-1928Mass production-1942 1940
Tetracycline 1950 1959
Erythromycin 1953 1968
Methicillin 1960 1962
Gentamicin 1967 1979
Vancomycin 1972 1988/2002
Imipenem/Ceftazidime 1985 1998/1987
Levofloxacin 1996 1996
Linezolid 2000 2001
Daptomycin 2003 2014
Ceftaroline 2010 2011
Telavancin 2013 2019
Tedizolid phosphate/Dalbavancin 2014 2016/2015
Delafloxacin 2017 2019
Omadacycline 2018 -
Iclaprim 2019 -
Cefiderocol 2020 -
The introduction of a new drug to the market generally takes 10–15 years, with a huge budget,
and most of the developed drug candidates fail the clinical stages due to their poor pharmacokinetic
properties. Therefore, alternative and novel approaches to develop new drugs, especially antibiotics,
should be established urgently. Most of the strategies that are being used today are based on prodrugs
and the design of new molecules, but the latter process has disadvantages in that it is expensive and
time-consuming. The prodrug approach is more efficient and cheaper, and about a tenth of marketed
drugs are classified as prodrugs [4].
In this review, we focus on newly developed antibiotic prodrugs and their discovery to fight the
dilemma of the century: antibiotic resistance.
2. Prodrugs
Prodrugs are pharmacologically inactive compounds that inter- or intra-convert inside the body
into active forms and non-toxic moieties by enzymatic or chemical reactions. In prodrug design, the
addition or removal of certain parts of the parent drug can alter its bioavailability, absorption, and
permeability without affecting its pharmacological activity. Prodrugs are classified into three types:(1)
carrier-linked prodrugs in which the active drug is linked to a promoiety, which is removed by an
enzymatic or chemical reaction to release the active drug (Figure 1),(2) bioprecursor prodrugs in which
a molecular modification is made to the active drug and that can undergo molecular modification by
oxidation or reduction reactions to release the active drug, and finally (3) double prodrugs that are
attached to each other by two linkers that can be cleaved by different mechanisms, such as a co-drug,
in which two biologically active drugs are linked in a single molecule.
The prodrug approach is now very popular, and it is not just used to alter the physicochemical
parameters but is also used to alter many molecular and cellular factors such as influx/efflux membrane
transporters and the expression/distribution of cellular proteins, in addition to drug targeting and
delivery to enhance treatment and therapeutic efficacy [4–9].
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bacampicillin (3) andhetacillin (4) (Figure 2) are all ester prodrugs that were developed to improve 
ampicillin bioavailability. Another form of prodrug is made by attaching a linker to the active drug 
to combine it with other antibiotics or different drugs such as sultamicillin (5) (Figure 2), which is a 
prodrug that links ampicillin and sulbactam by a methylene group [10–13]. Other prodrugs were 
developed to improve the activity of existing antibiotics including ethionamide (6), isoniazid (7) and 
pyrazinamide (8) (Figure 2), used to treat Mycobacterium tuberculosis. In addition, metronidazole (9) 
(Figure 2) acts as a prodrug, which is used for the treatment of Helicobacter pylori and anaerobic 
infections. Metronidazole requires reduction by specific enzymes to be activated; the redox 
intermediate could be responsible for killing the microorganisms by targeting intracellular 
components such asthe bacterial cell membrane, RNA, DNA and proteins. Resistance to 
Metronidazole has been reported especially in H. Pylori, but its mechanism of action is not well 
known [1,14]. 
Ceftaroline fosamil (10) (Figure 2) is an example of cephalosporin prodrugs that upon activation 
give the active metabolite ceftaroline, which acts by binding to penicillin-binding proteins that inhibit 
bacterial cell wall synthesis (Figure 3).Ceftaroline fosamil has potent activity against the bacteria 
causing community-acquired bacterial pneumonia (CABP), such as multidrug-resistant Streptococcus 
pneumoniae(MDRSP), penicillin-resistant Streptococcus pneumonia (PRSP) and methicillin-resistant 
Staphylococcus aureus (MRSA) [15]. 
Figure 1. A diagram illustrating the prodrug concept.
Most of the β-lactam antibiotics are poorly absorbed, and the prodrug approach was used
to improve their oral bioavailability.Pivampicillin (1) (Figure 2) is an ampicillin derivative that is
considered one of the first prodrugs to be developed, which is enzymatically hydrolyzed by esterases
to give the active drug ampicillin, with inactive pivalic acid. Moreover, talampicillin (2), bacampicillin
(3) andhetacillin (4) (Figure 2) are all ester prodrugs that were developed to improve ampicillin
bioavailability. Another form of prodrug is made by attaching a linker to the active drug to combine it
with other antibiotics or different drugs such as sultamicillin (5) (Figure 2), which is a prodrug that
links ampicillin and sulbactam by a methylene group [10–13]. Other prodrugs were developed to
improve the activity of existing antibiotics including ethionamide (6), isoniazid (7) and pyrazinamide
(8) (Figure 2), used to treat Mycobacterium tuberculosis. In addition, metronidazole (9) (Figure 2) acts as a
prodrug, which is used for the treatment of Helicobacter pylori and anaerobic infections. Metronidazole
requires reduction by specific enzymes to be activated; the redox intermediate could be responsible for
killing the microorganisms by targeting intracellular components such asthe bacterial cell membrane,
RNA, DNA and proteins. Resistance to Metronidazole has been reported especially in H. Pylori, but its
mechanism of action is not well known [1,14].
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Figure 2. Chemical structures of pivampicillin, talampicillin, bacampicillin, hetacillin, Sultamicillin,
ethionamide, isoniazid, pyrazinamide, metronidazole and ceftaroline fosamil.
Ceftaroline fosamil (10) (Figure 2) is an example of cephalosporin prodrugs that upon activation
give the active metabolite ceftaroline, which acts by binding to penicillin-binding proteins that inhibit
bacterial cell wall synthesis (Figure 3).Ceftaroline fosamil has potent activity against the bacteria
causing community-acquired bacterial pneumonia (CABP), such as multidrug-resistant Streptococcus
pneumoniae(MDRSP), penicillin-resistant Streptococcus pneumonia (PRSP) and methicillin-resistant
Staphylococcus aureus (MRSA) [15].
As we mentioned earlier, most of the antibiotics that have been developed over the decades
encountered bacterial resistance, which formed a wall in front of research and caused large
pharmaceutical companies to abandon already-registered antibiotics [2].
Molecules 2020, 25, 1543 5 of 16
Molecules 2020, 25, x FOR PEER REVIEW 5 of 17 
 
 
Figure 3. The activation of ceftaroline fosamil prodrug. 
As we mentioned earlier, most of the antibiotics that have been developed over the decades 
encountered bacterial resistance, which formed a wall in front of research and caused large 
pharmaceutical companies to abandon already-registered antibiotics [2]. 
3. Prodrug Applications Against Resistant Bacterial Pathogens 
In combating antibiotic resistance, prodrugs have been applied either to revive antibiotics that 
possess activity against resistant pathogens—but that cannot be used clinically because of their 
suboptimal pharmacokinetics—or as a targeting drug tool to overcome the resistance barriers and 
minimize host toxicity. Herein, we describe the recently reported antibiotic prodrugs for which the 
prodrug approach was the key to fight resistance. 
3.1. A β-Lactamase-Activated Ciprofloxacin Prodrug 
The most important and prevalent determinant of antibiotic resistance is the expression of β-
lactamase enzymes, which hydrolyze the β-lactam antibiotics, preventing their interaction with the 
penicillin-binding proteins, their therapeutic targets. Extended-spectrum β-lactamases that have the 
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3. Prodrug Applications against Resistant Bacterial Pathogens
In combating a tibiotic resistance, prodrugs have been ppli d either to revi antibiotics that
possess activity against resistant pat ogens—but that cannot be used clinically because of their
suboptimal pharmacokinetics—or as a targeting drug tool to overcome the resistance barriers and
minimize host toxicity. Herein, we describe the recently reported antibiotic prodrugs for which the
prodrug approach was the key to fight resistance.
3.1. A β-Lactamase-Activated Ciprofloxacin Prodrug
The most important and prevalent determinant of antibiotic resistance is the expression
of β-lactamase enzymes, which hydrolyze the β-lactam antibiotics, preventing their interaction
with the penicillin-binding proteins, their therapeutic targets. Extended-spectrum β-lactamases
that have the ability to cleave a wide range of β-lactam antibiotics, such as the CTX-M class
(extended-spectrum β-lactamases active on CefoTaXime, first isolated in Munich), are of particular
concern [16–18]. Broad-spectrum antibiotics, like ciprofloxacin, are increasingly used to treat i fections
caused by β-lactam-resistant bacterial infections, especially Escherichia coli-caused urinary tract
infections [19]. The problem is that the use of broad-spectrum antibiotics disrupts the microbiota,
the beneficial gastrointestinal bacteria, which normally lead to secondary infections caused by other
antibiotic-resistant bacteria [20,21].
A novel cephalosporin-fluoroquinolone prodrug was developed by Evans et al. [22]. The prodrug
was designed to selectively deliver a broad-spectrum antibiotic, ciprofloxacin, to only β-lactamase
expressing bacteria, while having minimal effects on bacteria that do not express this feature of
resistance, the β-lactamase enzymes. In this approach, it was meant for the prodrug motif to enable
substrate turnover rather than inhibit the β-lactamase enzyme. A cephalosporin core was selected
as the β-lactam component, as cephalosporins are well-known β-lactams efficiently hydrolyzed by
β-lactamases. Generally, cephalosporins are considered good prodrug moieties because they allow the
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bioreversible modification of other active drugs by the conjugation of one of their functional groups at
the 3′-position of the cephem core.
To achieve the desired selectivity profile, ciprofloxacin was attached via the carboxylic acid to give
the 3′-cephem ester. To reduce the antibacterial activity of the intact prodrug, a program of optimization
was undertaken by a modification to the cephalosporin portion. A cephalosporin analog with a methyl
group at the α-position relative to the amide carbonyl of the reference compound cephalothin gave the
best results. Overall, the prodrug exhibited aβ-lactamase-mediated intracellular release of ciprofloxacin
upon cleavage of the cephalosporin (Figure 4), selectivity toward β-lactamase-expressing E. coli, no
activity on non-β-lactamase expressing bacteria, and very little activity of the intact prodrug [22]. This
strategy of prodrug application opens the gate for using broad-spectrum antibiotics to treat resistant
pathogens in a selective manner.
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development, including PYRRO-C3D (pyrro-cephalosporin-3′-diazeniumdiolate) (11), and DEA-
C3D(diethylamin-cephalosporin-3′-diazeniumdiolate)(12) (Figure 6). DEA-C3D, the prototypical 
example of a C3D, contains the phenacetyl side chain of cefaloram, a first-generation cephalosporin, 
and the diazeniumdiolate NO donor. In vitro studies have shown that DEA-C3D was able to disperse
biofilms formed by multiple clinical isolates of Pseudomonas aeruginosa, and that when combined with
colistin, it caused the near-complete eradication of P. aeruginosa biofilms [25].  
Another representative of C3Ds is PYRRO-C3D, which contains the diazeniumdiolate NO donor 
PYRRO-NO. PYRRO-C3D undergoes β-lactam cleavage by transpeptidases. Transpeptidase-reactive 
C3Ds have a dual action in which they act as NO-mediated anti-biofilm agents and possess intrinsic 
β-lactam-mediated antibacterial effects [23]. It was found that PYRRO-C3D can reduce the viability 
of planktonic and biofilm pneumococci in the absence of β-lactamases. A study that was done to test 
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3.2. Cephalosporin-3-Diazeniumdiolate
Cephalosporin-3′-diazeniumdiolates (C3Ds) are a new class of nitric oxide (NO) donor
prodrugs. These prodrugs have a β-lactam ring in their structures and are designed to selectively
deliver NO to bacterial infection sites after the reaction with β-lactamases and the cleavage
of β-lactam by transpeptidase (Figure 5) [23,24]. Currently, there are some C3Ds that are
under development, including PYRRO-C3D (pyrro-cephalosporin-3′-diazeniumdiolate) (11), and
DEA-C3D(diethylamin-cephalosporin-3′-diazeniumdiolate) (12) (Figure 6). DEA-C3D, the prototypical
example of a C3D, contains the phenacetyl side chain of cefaloram, a first-generation cephalosporin,
and the diazeniumdiolate NO donor. In vitro studies have shown that DEA-C3D was able to disperse
biofilms formed by multiple clinical isolates of Pseudomonas aeruginosa, and that when combined with
colistin, it caused the near-complete eradication of P. aeruginosa biofilms [25].
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Another representative of C3Ds is PYRRO-C3D, which contains the diazeniumdiolate NO donor
PYRRO-NO. PYRRO-C3D undergoes β-lactam cleavage by transpeptidases. Transpeptidase-reactive
C3Ds have a dual action in which they act as NO-mediated anti-biofilm agents and possess intrinsic
β-lactam-mediated antibacterial effects [23]. It w s found that PYRRO-C3D c n reduce the viability of
planktonic and biofilm pneumococci in the abs nce of β-lactamases. A study that was done to test the
ctivity of PYRRO-C3D against a non-typeable Haemophilus influenza (NTHi) biofilms showed that
PYRRO-C3D enhanced the efficacy of azithr mycin against NTHi biofilms and can ct as a promising
adjunctive treatment for reducing biofilm-associ ted antibiotic tol rance [23,26].
3.3. Triclosan Glycoside Prodrugs
The idea of using glycoside de ivatives of antibacterials as bact rium-targeting prodrugs came
abou as a result of the discovery of glyco idase enzyme expression in bacteria [27,28]. Triclo an is an
antibact rial d antifungal agent that has be n us d as a disinfectant. Triclosan acts by inhibiting
fatty acid synthesis, and in high concentrations, it disrupts the cell wall [28]. This agent is used only
topically due to its low solubility at physiological pH. It was expected that glycoside derivatives on the
hydroxyl group of triclosan would enhance bacterial uptake by active transport. Glycoside derivatives
of triclosan (α-D-glycopyranosides and β-D-glycopyranosides) (13) (Figure 6) have the ability to inhibit
the growth of Gram-positive and Gram-negative bacteria and showed potent, selective antibacterial
activity and increased aqueous solubility compared to triclosan. This earned them the advantage to be
used orally for the treatment of systemic infections [29].
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3.4. Enterobactin-Antibiotic Conjugates
The prodrug approach has been used to attain drug targeting with certain antibiotics. Zheng and
Nolan [30] presented a strategy to achieve intracellular antibiotic targeting, as well as pathogen-specific
activity, by making siderophore-antibiotic conjugates. This strategy is based on linking antibiotics with
enterobactin—a siderophore that has receptors on bacterial surfaces and is responsible for the uptake
of iron—generating inactive prodrugs. This linkage enables the uptake of the siderophore along with
the antibiotic linked to it, and then the hydrolysis of the conjugate and the activation of the antibiotic
take place in the bacterial cytoplasm, involving specific cytoplasmic enzymes [31]. Enterobactin (Ent)
is a tricatecholatesiderophore (iron carrier) naturally produced by enteric Gram-negative bacteria
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like E. coli, and is secreted in the host vertebrate to acquire iron. Recently, enterobactin-ciprofloxacin
conjugate (14) (Figure 6) discovery was reported by Neumann et al. [30]. Ent–Ciprofloxacin is a
conjugate that has ciprofloxacin attached to an alkyl linker at one of the catechols of Ent; the result
is an inactive prodrug of ciprofloxacin that is guided into the cytoplasm by Ent uptake machinery
(Figure 7). Intracellularly, the prodrug is activated by the cytoplasmic esteraseIroD, an enzyme that is
only expressed by E. coli that express the iroA gene cluster—a pathogen-associated cluster—which
makes the prodrug selective for E. coli that have the iroA gene cluster, while having no activity against
nonpathogenic clusters [30].Molecules 2020, 25, x FOR PEER REVIEW 10 of 17 
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Ent–Ciprofloxacin was not the first Ent to be used for intracellular delivery in E. coli. Ent
conjugation was tried earlier on the β-lactams ampicillin and amoxicillin. Ent–amoxicillin/ampicillin
conjugates exert antibacterial activity after being recognized by outer membrane-siderophore receptors
and transported into E. coli via the outer membrane transporters FepA and IroN. The prodrugs had
antimicrobial activity enhanced up to 1000-fold, relative to the parent drugs, against uropathogenic
E. coli, and selectively kill uropathogenic E. coli that express the IroN receptor [31,32].
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3.5. Antimicrobial Peptide Prodrugs
Antimicrobial peptides (AMPs), also known as host defense peptides, are peptidic molecular
mediators of innate immunity found in multicellular organisms that have antimicrobial activity [33,34].
AMPs exert direct microbicidal activity by having an amphipathic and cationic nature that enables
them to be inserted in microbial cytoplasmic membranes, increasing permeation and causing cell
lysis [34–36]. Interests in the development of AMP antibiotics, especially against resistant bacteria, are
increasing [37–41], but unwanted cell toxicity forms a major limitation for their improvement. The
prodrug strategy is a promising solution to solve the toxicity problem and fulfill bacterial selectivity,
by making AMP prodrugs that permit the cationic feature to be transiently reduced by the reversible
conjugation of an anionic promoiety and that can be activated by specific bacterial enzymes [42].
This strategy was applied in a study in which two prodrugs of the AMPs, P18 and WMR (W
and R modified myxinidin peptide), were developed. P18 is a hybrid of cecropin and magainin, two
innate immunity peptides from the moth Hyalophoracecropia and the frog Xenopuslaevis, respectively.
WMR is a myxinidin analog from the hagfish Myxineglutinosa. The prodrugs were prepared by
amidation at the parent P18 and WMR C-termini and the elongation of the N-termini with the
residual amino acid AAG motif, from the neutrophil elastase sensitive linker, to give the pro-peptides
(prodrugs) pro-P18 and pro-WMR, of the sequencesAc-EEEEAAAGkwklfkklpkflhlakkf-NH2 and
Ac-EEEEAAAGwglrrllkygkrs-NH2 respectively (uppercase letters denote L-amino acids and lowercase
letters denote D-amino acids, Ac- denotes N-terminal acetylation, and -NH2 denotes C-terminal
amidation). The study described the action of the two AMPs and their prodrugs on models of bacterial
and mammalian cells using the membrane permeabilization assay. It was found that the pro-peptides
exerted a broad-spectrum antibacterial effect which was associated with membrane disruption. Both
pro-peptides induced similar and potent permeabilizations of the bacterial model liposomes. As for
the effect on the human model liposome, pro-P18 was 9-fold more lytic than pro-WMR. Substantially,
the on-target selectivity between bacterial and human membranes was improved, reducing the toxicity
against human membranes for both candidate peptides. This prodrug strategy suggests that the target
selectivity of AMP can be improved by the near-complete neutralization of the AMP’s net charge,
which is likely to reduce their propensity to affect biological membranes [42].
Another implementation of the prodrug approach to impart selective targeting for AMPs
was the synthesis of β-lactam-AMP conjugates: prodrugs in which AMPs are conjugated with
cephalosporins to trigger selectivity by bacterial β-lactamases. The binding between the β-lactam
core of the prodrug and the β-lactamase enzyme will trigger the release of the active AMP inside
the resistant, β-lactamase expressing, bacteria. Cephalothin-Bac8c (15) (Figure 6) is a conjugate
that links cephalothin, a first-generation cephalosporin, with Bac8c—an AMP derived from the
bovinedodecapeptidebactenecin [43]—through a carbamate-1,4-triazole linker. Cephalothin-Bac8c
is a candidate for β-lactam-AMP prodrug conjugates with promising antibacterial activity targeting
resistant extended-spectrum β-lactamase producing Enterobacteriaceae [44].
3.6. Prodrugs of 5-Modified 2′-Deoxyuridines
Pyrimidine nucleoside derivatives with a lengthy substituent at the C-5 position of the nucleobase
were shown to have in vitro antimicrobial activity [45,46]. The mechanism of action is unclear, but it
was shown that some derivatives selectively inhibit the microorganismic enzyme flavin-dependent
thymidylate synthase (ThyX), an enzyme that is absent in mammals. Other derivatives demonstrated
destruction of the mycobacterial cell wall [47].
Negryaet et al. [48] have recently synthesized a set of pyrimidine nucleoside derivatives. The
nucleoside derivatives showed antitubercular activity. Two compounds of the derivatives had
significant activity against M. tuberculosis resistant strains; the compounds are 5-dodecyloxymethyl
2′deoxyuridine and 5-[4-decyl-(1,2,3-triazol-1-yl) methyl]-2′deoxyuridine. Although the nucleoside
derivatives showed high activity, their water solubility was low because of the presence of bulky
lipophilic substituents. The poor water solubility made it troublesome to study the antibacterial activity
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of the nucleoside derivatives on different bacteria. The prodrug approach was used to enhance the water
solubility of the 5-C substituted nucleosides. Carrier-linked prodrugs of 5-modified 2′-deoxyuridines
(16) (Figure 6) were synthesized by Negryaet et al. [48] using a carbonate group to link a triethylene
and tetraethylene glycol moiety to the 3′- and 5′-hydroxyl groups of the parent compounds. The
obtained compounds were at least two orders of magnitude more soluble than their parent drugs, with
a hydrolysis time of 5–12 h. The prodrugs showed moderate activity against some Gram-positive
bacteria and low cytotoxicity towards mammalian cells. Their activity included the killing of resistant
strains of S. aureus and Mycobacteriumsmegmatis [48].
3.7. The Tebipenempivoxil Prodrug
Tebipenem (SPR859) is a β-lactam antibiotic belonging to the carbapenem family and is active
against Gram-negative and Gram-positive pathogens, but its high hydrophilicity limits its oral
absorption. Tebipenempivoxil (17) (Figure 6) is an orally-administrated pivaloyloxymethyl ester
prodrug of tebipenemwith better absorption and high bioavailability, which is currently approved only
in Japan as a granule formulation for the treatment of ear, nose, throat and respiratory infections in
pediatrics. Tebipenempivoxil HBr salt is currently under development for the treatment of complicated
urinary tract infections in adults. Pharmacokinetics and pharmacodynamics activity showed that
tebipenempivoxil HBr is a good alternative oral treatment for resistant Gram-negative pathogens and
may serve as a new antibacterial agent [49].
3.8. Avibactam Prodrugs
β-lactamase inhibitors restored the effectiveness of β-lactam antibiotics. None of the β-lactamase
inhibitors other than clavulanic acid are orally available. This is the case of avibactam, which is a
potent diazabicyclooctane inhibitor of a wide spectrum of β-lactamases but lacks the proper oral
bioavailability. Gordon et al. [50] have reported the synthesis and testing of avibactam O-neopentyl
ester prodrugs (18) (Figure 6) designed to mask the charged sulfate moiety in avibactam’s structure,
a moiety that causes a major obstacle for oral absorption. Coupled with anappropriate antibiotic,
avibactam has the potential to treat serious Gram-negative infections without the need for intravenous
injections [50].
3.9. Tedizolid Phosphate (TR701)
Tedizolid phosphate (19) (Figure 6) is an orally absorbed phosphate prodrug of tedizolid (TR700):
an antibiotic of the new class oxazolidinones. Among this class, linezolid is the only marketed
oxazolidinone. Oxazolidinone antibiotics are protein synthesis inhibitors that bind to the 50S ribosome
and prevent the formation of the 70S complex [51]. Oxazolidinones are unlikely to have cross-sensitivity
with other antibiotics because of a unique site of action that is the ribosomal peptidyltransferase
center [52].
Tedizolid was found to be 4–8 fold more potent than linezolid. It is provento be active against
methicillin-sensitiveand methicillin-resistant Staphylococcus aureus, various strains of Enterococcusfaecalis
and Streptococcus spp. More importantly, it had activity against linezolid-resistant isolates; this
activity and potency are suggested to happen due to additional binding site interactions [53,54].
All of this demonstrates that tedizolid phosphate could be a new treatment for multidrug-resistant
Gram-positive bacteria.
3.10. FtsZ-Targeting Benzamide Prodrugs
Fts-Z (Filamenting temperature-sensitive mutant Z) is a prokaryote-specific protein involved in
bacterial cell division; this protein represents a new antibiotic target. The compound PC190723 was
among the first FtsZ-Targeting Benzamides to be proved effective against methicillin-sensitive and
resistant Staphylococcus aureus (MSSA and MRSA). The poor pharmacokinetics and drug-like properties
of PC190723 hindered its clinical development, but the development of the N-Mannich base prodrug
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TXY436 (20) (Figure 6) followed, which exhibited oral bioavailability and efficacy, as well as enhanced
intravenous efficacy [55].
Despite the enhanced pharmaceutical properties of TXY436, it still required high efficacious doses.
A new prodrug TXA709 (21) (Figure 6) was designed, based on TXY436, to enhance the metabolic
stability by having a CF3 functionality replacing the Cl groups on the pyridyl ring. The prodrug
TXA709 is rapidly converted in vivo to TXA707: an active, benzamide-derivative, FtsZ-Targeting
compound (Figure 8). As a result, TXA709 has a 6.5-fold-longer half-life and a 3-fold-greater oral
bioavailability relative to TXY436, a potent bactericidal activity against resistant S. aureus strains, and
minimal toxicity towards mammalian cells [56].
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3.11. Carvacrol Prodrugs
Carvacrol is a natural monoterpene; it is a component of phenolic essential oils particularly
abundant in plants belonging to the Lamiaceae family. Carvacrol is a compound with emerging
potential for application in microbial infection management because of its antimicrobial activity. Biofilm
formation is one mechanism by which bacteria have developed resistance to drugs. Carvacrol can
inhibit the growth of bacterial biofilms and interfere with biofilm formation, hence carvacrol has
recently attracted much attention [57].
Carvacrol has an amphipathic structure that allows it to spread through the polar matrix of
bacterial biofilms and to disrupt bacterial membranes; it increases the fluidity, permeability, and
perturbation of the cytoplasmatic membranes. Carvacrol acts on biofilms produced by Gram-positive
bacteria, especially those produced by S. aureus and Staphylococcus epidermidis. It disintegrates the outer
membrane of Gram-negative bacteria as well [58].
The poor physicochemical properties of carvacrol like low water solubility, low chemical stability
and high volatility restrain its potential therapeutic uses. These disadvantages can be overcome by
the prodrug approach. Recently, 23 carvacrol prodrugs were synthesized and evaluated for their
activity against selected Gram-positive and Gram-negative bacteria. Hydrophilic carvacrol prodrugs,
prepared using polar natural groups like amino acids, showed increased water solubility. Lipophilic
prodrugs were obtained by the prenylation of the hydroxyl group of carvacrol. Two lipophilic prodrugs
(WSCP18-19) (22) (Figure 6) showed the most promising results, with antibacterial and anti-biofilm
activities against S. aureus and Staphylococcus epidermidis. Moreover, the prodrugs exerted increased
stabilities in human plasma and simulated fluids. Additionally, all of the obtained prodrugs were
nontoxic to mammalian cells [58].
3.12. ADC111, ADC112 and ADC113
The need for broad-spectrum antibiotics can be met by the development of prodrugs that
are activated by enzymes that are bacterium-specific, to give reactive compounds that could kill
persisters and accumulate over time. Hence, a screen of 55,000 compounds of prodrugs was done
by Fleck et al. [59]. The screen was directed to prodrugs that have been discarded in conventional
high-throughput screening campaigns due to the lack of specificity of the mechanism of action. The
screen was based on identifying compounds that nonspecifically inhibit the reduction of alamarBlue, a
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viability dye, and then testing for cytotoxicity and eliminating generally-toxic compounds. Twenty
hit compounds were active against E. coli. Out of the 20 hits, three prodrugs were further developed:
ADC111 (23), ADC112 (24) and ADC113 (25) (Figure 6).
ADC111 is an analog of the nitrofuran prodrug, nitrofurantoin, an antibacterial that is used to treat
urinary tract infections [60]. ADC111′s activity depends on the presence of the activating nitroreductase
enzymes. ADC111 was considerably more active against E. coli and less toxic against mammalian
cells compared to its analog nitrofurantoin. Its activity was greater against growing cells than against
persister cells [59]. ADC112 is an analog of the antimicrobial tilbroquinol, and its mechanism of action
is unknown [61]. ADC112 achieved the complete sterilization and killing of even the stationary cells
of E. coli. This prodrug was the most potent one against E. coli [59]. ADC113 is a compound with a
di-ketone functionality that does not belong to an approved antimicrobial class. ADC113 had excellent
killing activity against growing E. coli cells and exerted good killing of stationary cells. Its killing in
biofilms was comparable to ciprofloxacin. The three prodrugs had a good spectrum of antimicrobial
activity and showed good-to-excellent activity against biofilms and stationary cultures [59].
4. Conclusions
The emergence of bacterial pathogens that are resistant to antibiotics and the shortage of
conventional antibiotics to treat infections associated with resistant bacteria have created an urgent
need for new treatment options. Unfortunately, bacteria produce and acquire genetic changes to support
their survival. Enzymatic degradation, target modification, the overexpression of efflux pumps and
decreased drug uptake are all mechanisms exerted by bacteria to obtain treatment resistance. Moreover,
chronic infections are characterized by the accumulation of bacterial persisters in biofilms, shielding
them from the immune system and conventional antibiotics. The success of the prodrug approach in
resolving the limitations of drugs in a relatively short time has encouraged research into antibiotic
prodrugs, a strategy that will enable the eradication of resistant bacteria by upgrading the existing
antibiotics. One of the major determinants of resistant bacteria is their expression of β-lactamase
enzymes; this feature was exploited in developing a β-lactam-activated prodrug in which the killing
activity is activated within resistant bacteria and by their enzymes. Cephalosporin-ciprofloxacin
conjugates, cephalosporin-3′-diazeniumdiolates and cephalothin-Bac8c conjugates are such examples.
Many approaches include the development of prodrugs to enable or enhance the oral administration of
certain antibiotics, like triclosan glycoside prodrugs, 5-modified 2′-deoxyuridines, tebipenempivoxil,
prodrugs of FtsZ-targeting benzamides, avibactam prodrugs and tedizolid phosphate. Prodrugs of
carvacrol attained increased solubility and enhanced chemical stability. Some prodrugs were designed
to enhance drug uptake by bacteria, like entrobactin-ciprofloxacin (by uptake by iron carriers), and P18
and WMR AMP-prodrugs, which impart selectivity and decreased toxicity. Further to the development
of novel prodrugs, the screening for overlooked antibacterial prodrugs presents new potential and a
platform for antimicrobial discovery.
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